Literature review · Sleep research

DSIP

Delta sleep-inducing peptide has been investigated in small sleep experiments. Early positive observations coexist with later studies reporting weak or clinically limited effects, so the name should not be read as a proven sleep-aid claim.

By HeartPep · Reviewed · 4 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The human studies selected here are old, small and short. Their mixed findings do not establish a reliable modern insomnia treatment or effects of supplied nasal or vial products.

Identity & scope

DSIP is the abbreviation used for delta sleep-inducing peptide in the selected papers. The catalogue label does not independently confirm the sequence, identity or preparation used in those experiments.

Catalogue labels covered: DSIP.

What the research shows

  • An early six-volunteer experiment reported acute and subsequent sleep changes.
  • Two later insomnia investigations found that apparent improvements were weak, affected by baseline or placebo differences, or unlikely to provide substantial clinical benefit.
  • A 14-patient report described improved sleep and daytime performance, illustrating the inconsistency across small studies rather than resolving it.

Critical interpretation

Why the positive reports do not settle the question

The early healthy-volunteer experiment and the 14-patient insomnia report provide reasons to investigate DSIP, but neither supplies a large, durable clinical comparison. Later weak or negative results must remain visible alongside them. Counting how many papers are positive is less informative than examining their design, baseline balance, population and measured outcome. [1] [4] [2]

Meaningful sleep outcomes need consistent evidence

A shift in one sleep stage or a laboratory-night measurement may not correspond to a worthwhile improvement in perceived sleep or daytime functioning. The 1992 study is informative because apparent objective changes coexisted with unchanged subjective sleep quality. Replication should reconcile these outcomes rather than selecting whichever measure looks most favourable. [3]

Limitations & uncertainties

  • Brief laboratory observations cannot establish sustained benefit, everyday functioning or long-term safety.
  • Different populations and study designs make simple comparison of positive and negative results difficult.
  • These reports do not validate any catalogue formulation, its delivery characteristics or its batch quality.

Open research questions

  • Would larger independently replicated studies using meaningful patient-reported outcomes show a durable effect?
  • Can any result be reproduced with a precisely identified, characterized formulation?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior (opens in a new tab)

Schneider-Helmert D et al. (1981). Int J Clin Pharmacol Ther Toxicol. · PMID 6895513

Design & population
Double-blind crossover experiment in six healthy volunteers.
What the study found
The investigators reported more acute sleep and later changes in sleep onset and efficiency.
Limits on interpretation
Extremely small early experiment in healthy volunteers, not proof of sustained insomnia relief.
Human studyNamed compoundAbstract / record checked

2. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs (opens in a new tab)

Monti JM et al. (1987). Int J Clin Pharmacol Res. · PMID 3583493

Design & population
Double-blind crossover insomnia study using polysomnography.
What the study found
Several sleep comparisons were not significant; other differences already existed at baseline. The authors judged clinical relevance limited.
Limits on interpretation
Short observation period and baseline imbalances complicate interpretation.
Human studyNamed compoundAbstract / record checked

3. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study (opens in a new tab)

Bes F et al. (1992). Neuropsychobiology. DOI: 10.1159/000118919 (opens in a new tab) · PMID 1299794

Design & population
Double-blind parallel-groups laboratory study in 16 chronic insomnia patients.
What the study found
Some objective changes were weak; subjective sleep quality did not improve. The authors found little basis for major therapeutic benefit.
Limits on interpretation
Small and short study; some apparent differences may reflect change in the placebo group.
Human studyNamed compoundAbstract / record checked

4. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (opens in a new tab)

Schneider-Helmert D. (1987). Eur Neurol. DOI: 10.1159/000116143 (opens in a new tab) · PMID 3622582

Design & population
Placebo-controlled double-blind study of 14 chronic insomnia patients with sleep and daytime-performance measurements.
What the study found
The report describes improved night sleep and daytime alertness/performance over a short observation period.
Limits on interpretation
Very small, brief study; its positive conclusions conflict with later reports of clinically limited benefit.

Search & review scope

Targeted PubMed searches for controlled sleep experiments, retaining both positive and weak or negative results. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.. Checked 9 November 2026.

Selected primary human sleep experiments; not a survey of all DSIP biology.

Abstract-based narrative selection, not a systematic review. Older full texts and comprehensive adverse-event data were not assessed. Incomplete PubMed record retrieval limits linked-notice checking; absence of a located correction is not complete publication-status clearance.

Recorded search terms
  • site:pubmed.ncbi.nlm.nih.gov DSIP 1299794
  • site:pubmed.ncbi.nlm.nih.gov/1299794/
  • site:pubmed.ncbi.nlm.nih.gov delta sleep inducing peptide double blind crossover healthy volunteers sleep 1981
  • site:pubmed.ncbi.nlm.nih.gov "delta sleep-inducing peptide" placebo insomnia
  • site:pubmed.ncbi.nlm.nih.gov/3622582/

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. DSIP: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/dsip.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes